According to a recent announcement, the first patient has been dosed in a phase 2 open label extension (OLE) trial assessing 25 mg daily subcutaneous injections of nomlabofusp (Larimar Therapeutics), formally known as CTI-1601, in patients with Friedreich ataxia (FA). The initial data from the OLE study on nomlabofusp, a novel investigational protein replacement therapy designed to address the root cause of FA by delivering frataxin to mitochondria, is anticipated in the fourth quarter of 2024.1
The OLE study will investigate the safety and tolerability, pharmacokinetics, and tissue frataxin levels in peripheral tissues as well as other exploratory pharmacodynamic markers following treatment with nomlabofusp. During the trial, clinical measures collected will be compared with data from a synthetic control arm derived from patients from the Friedreich’s Ataxia Clinical Outcome Measures Study database. Additionally, data from the 50 mg cohort of the phase 2 dose exploration study and from the 25 mg dose in the OLE study will be submitted for FDA review to escalate the dose in the OLE study because of the continued partial clinical hold.
Top Clinical Takeaways
- Nomlabofusp may represent a novel approach to treating Friedreich ataxia by targeting the root cause of the disease.
- The phase 2 trial aims to assess both safety and efficacy parameters, including tissue frataxin levels, in patients with Friedreich ataxia.
- Collaboration with regulatory authorities is essential to address any safety concerns and move the treatment forward.
“We are pleased to dose the first patient in our OLE study, further advancing the nomlabofusp clinical program and building on the successful completion of our phase 2 dose escalation study,” Carole Ben-Maimon, MD, president, and chief executive officer of Larimar, said in a statement.1 “Importantly, the OLE study will inform on the long-term safety profile and tissue frataxin levels and provide a first look at real-life experience with self-administration by patients or administration by a caregiver.”
READ MORE: FDA Grants Fast Track Designation for Gene Therapy Candidate LX2006 in Friedreich Ataxia Cardiomyopathy
In July 2023, the FDA cleared the company’s 4-week, placebo-controlled exploration trial (NCT05579691) assessing CTI-1601 in doses of 50 mg and the OLE.2 In the exploration trial, ambulatory and nonambulatory individuals with FA aged at least 18 years old will be randomly assigned 2:1 to either CTI-1601 or placebo daily via subcutaneous injections for the first 14 days, and then every other day until day 28. The trial features 2 cohorts, a 25 mg and 50 mg dosed group. Cohort 1, assessing a 25 mg dose of CTI-1601, includes 13 participants (9 on active treatment, 4 on placebo) while Cohort 2, which is initiating, will include 12-15 participants randomized to either CTI-1601 or placebo in 50 mg dose settings.